Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Primary and secondary hypertriglyceridemia is common in the general population, but the biochemical basis for this disease is largely unknown. With the use of transgenic technology, two lines of mice were created that express the human apolipoprotein CIII gene. One of these mouse lines with 100 copies of the gene was found to express large amounts of the protein and to be severely hypertriglyceridemic. The other mouse line with one to two copies of the gene expressed low amounts of the protein, but nevertheless manifested mild hypertriglyceridemia. Thus, overexpression of apolipoprotein CIII can be a primary cause of hypertriglyceridemia in vivo and may provide one possible etiology for this common disorder in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“High ApoC-III levels were shown to increase total triglyceride levels by an accumulation of VLDL and chylomicrons [166–169]”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [167]
In the citing paper
“These data are consistent with previous studies showing that transgenic mice with overexpression of human apolipoprotein C3 had hypertriglyceridemia due to decreased lipoprotein lipase activity,16”
From Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease (2010) · cites this paper as [16]
Citations
Cites
The Metabolic Basis of Inherited Disease.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-503_7 · Cited by 7,786
NF-κB: A pleiotropic mediator of inducible and tissue-specific gene control
Lenardo, M. J., & Baltimore, D. (1989) · Cell · doi:10.1016/0092-8674(89)90833-7 · Cited by 1,585
Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
Virgil Brown, W., & Baginsky, M. L. (1972) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(72)80149-9 · Cited by 491
Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424
Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
Wang, C. S., McConathy, W. J., Kloer, H. U., & Alaupovic, P. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111711 · Cited by 414
Karathanasis, S. K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6374 · Cited by 358
PLASMA TRIGLYCERIDE AS A RISK FACTOR FOR CORONARY HEART DISEASE
AUSTIN, M. A. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115130 · Cited by 352
Familial Deficiency of Apolipoproteins A-I and C-III and Precocious Coronary-Artery Disease
Norum, R. A., Lakier, J. B., Goldstein, S., Angel, A., Goldberg, R. B., Block, W. D., Noffze, D. K., Dolphin, P. J., Edelglass, J., Bogorad, D. D., et al. (1982) · New England Journal of Medicine · doi:10.1056/nejm198206243062503 · Cited by 304
Weintraub, M. S., Eisenberg, S., & Breslow, J. L. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112926 · Cited by 261
Self-citationWalsh, A., Ito, Y., & Breslow, J. L. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83374-9 · Cited by 241
Self-citation
Research works printed but not linked: 2
- COLE, T.G., BIOCOMMUNIQUE 4: 4 (1988).
- PROTTER, A. A., DNA-A JOURNAL OF MOLECULAR & CELLULAR BIOLOGY 3: 449 (1984).
Cited by
Items 501–543 of 543
Hypertriglyceridemia: the future of genetics to guide individualized therapeutic strategies
Moens, S. J. B., Hassing, C., Nieuwdorp, M., Stroes, E. S. G., & Dallinga‐Thie, G. M. (2013) · Clinical Lipidology · doi:10.2217/clp.13.23
Novel factors affecting clearance of triacylglycerol-rich lipoproteins from blood
Nilsson, S. K. (2010)
Sacks, F. M. (2000) · Springer eBooks · doi:10.1007/978-4-431-68424-4_2
Apolipoprotein C-III, An Important Player in Lipoprotein Metabolism
Fruchart, J., Barthelemy-Clavey, V., Luc, G., Dallongeville, J., Staels, B., & Auwerx, J. H. (1996) · Medical science symposia series · doi:10.1007/978-94-009-0311-1_74
Les animaux génétiquement modifiés
Baroukh, N., Vergnes, L., Ostos, M. A., Zakin, M. M., & Ochoa, A. (2000) · Annales de l Institut Pasteur / Actualités · doi:10.1016/s0924-4204(00)80017-7
Apolipoprotein C-III's role in cardiovascular diseases, a short review
Emilian, O. G. (2014) · ScienceOpen Research · doi:10.14293/s2199-1006.1.sor-med.afafp0.v1
Kim, Y. R., & Hong, S.-H. (2016) · Genes & Genomics · doi:10.1007/s13258-016-0431-5
Catapano, A. L. (1995) · Medical science symposia series · doi:10.1007/978-94-011-0039-7_36
Cholesteryl Ester Transfer Protein, CETP
静也, 山. (1996) · The Journal of Japan Atherosclerosis Society · doi:10.5551/jat1973.23.11_647
West, G. (2017) · OpenCommons - UConn (University of Connecticut)
Cheng, S., Pang, B., Gu, C., Sun, S., An, C., Zhang, Z., Li, J., & Liu, G.-J. (2017) · Frontiers in Laboratory Medicine · doi:10.1016/j.flm.2017.10.002
Dysrégulations de la production et de la clairance des lipoprotéines riches en triglycérides
Marmontel, O. (2018) · theses.fr (ABES) · doi:10.70675/bbd72f7dz89b7z4e60z8948z624ca506d486
General Discussion and Future Perspectives
Cassarini, C. (2019) · CRC Press eBooks · doi:10.1201/9780429448300-7
Elbaz, R., Elshaer, A., Sheriff, M., Othma, Y., Mahfouz, M., & Settin, A. (2017) · International Journal of Genomics and Data Mining · doi:10.29011/2577-0616.000114
Schultz, C., Berti, J. A., Rinaldi, J. D. C., & Ana, D. D. M. G. S. (2019) · Arquivos do Mudi · doi:10.4025/arqmudi.v23i3.51515
Galton, D. J., Mattu, R. K., & Stocks, J. (1994) · Developments in cardiovascular medicine · doi:10.1007/978-94-011-1130-0_21
Bighetti, E. J. B., Patrício, P. R., Casquero, A. C., Berti, J. A., & Oliveira, H. C. F. (2015)
Chang, Y., Hsueh, K., Liu, C.-H., Lo, Y.-L., Lin, Y., & Wang, Y. (2020) · Research Square · doi:10.21203/rs.3.rs-63439/v1
Implication de l'apolipoprotéine AV dans le déterminisme des hyperchylomicronémies
Charrière, S., Moulin, P., métaboliques, N. E. D. R. R., & Sciences-Santé, É. D. I. (2009) · OpenGrey (Institut de l'Information Scientifique et Technique)
Triglyceride-Rich Lipoproteins
Le, N., & Brown, W. V. (2000) · doi:10.1007/978-1-4757-9310-9_5
Triglyceride-Rich Lipoproteins
Le, N., & Brown, W. V. (2003) · doi:10.1007/978-1-4615-6484-3_5
(1993) · Elsevier eBooks · doi:10.1016/b978-0-12-121070-0.50010-8
Eshpulatov, A. S., Hoshimov, S. U., Kan, L. E., Ахмедова, Ш. С., Аминов, С. А., Хусаиновна, Т. Р., Shek, A. B., & Kurbanov, R. D. (2014) · Eurasian heart journal · doi:10.38109/2225-1685-2014-3-30-36
Gentechnisch veränderte Großtiere in der Biomedizin
Wolf, E., Kind, A., Aigner, B., & Schnieke, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-26042-1_9 · Cited by 2
Ferreira, E. G., Jimenes, D. R., Baptista, J. M. D. S., Teixeira, N. R., Sales, S. C. C. M., Wilxenski, A., Berti, J. A., & Barbosa, C. P. (2025) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv17n3-047
Martins, Y. A., Schultz, C., Rodrigues, N., Ravanelli, M. I. B., Visentainer, J. V., Santos, O. D. O., Berti, J. A., & Brunaldi, K. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152715
Gotto, A. M., Patsch, W., & Patsch, J. R. (1993) · Medical science symposia series · doi:10.1007/978-94-011-1703-6_40
Genetics of coronary heart disease
Naoumova, R. P., Cook, S. A., Cook, P. R., & Aitman, T. J. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511543555.025
Filippo, M. D. (2014) · theses.fr (ABES) · doi:10.70675/72090dcbz5e73z41d4zaaa1z93311c54faa8 · Cited by 1
Chackathayil, J. (2013) · University of Birmingham Institutional Research Archive (University of Birmingham)
Pathophysiology, diagnosis, and emerging treatments for Kaposi sarcoma: A clinical review
Zhou, M. H., Stirrat, T. P., Alam, M., Cesarman, E., Geskin, L. J., Schwartz, R. A., Tyring, S., Matushansky, I., & Lipner, S. R. (2026) · JAAD reviews. · doi:10.1016/j.jdrv.2026.03.004
Lipémie postprandiale et lactoferrine : le Lipolysis Stimulated Receptor comme cible potentielle
Ahmad, N. (2012) · theses.fr (ABES) · doi:10.70675/542d67dez25e7z40ffzadbfz6af5f5a80d3b
Régulation épigénétique de la lipolyse intravasculaire des triglycérides
Pinkele, C. (2015) · theses.fr (ABES) · doi:10.70675/c1f85e63z2bd1z45a6z89bbzc71288b94dd3 · Cited by 1
Apolipoprotein CIII as a therapeutic target in obesity-associated metabolic dysfunction
Valladolid‐Acebes, I., Berggren, P., & Juntti‐Berggren, L. (2026) · Advances in Biological Regulation · doi:10.1016/j.jbior.2026.101183
Characterization of genes involved in the metabolism of atherogenic lipoproteins in the mouse
Hoffer, M. J. V. (1993) · TNO Repository
Is Hypertriglyceridemia always a Risk Factor?
de Man, F. H. A. F., Hoffer, M. J. V., Smelt, A. H. M., Leuven, J. A. G., & van der Laarse, A. (1997) · Developments in cardiovascular medicine · doi:10.1007/978-94-009-0037-0_9
Metadata
- Authors
- Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., & Breslow, J. L.
- Affiliations
- Rockefeller University (US)
- Venue
- Science
- Published
- 1990-08-17
- Volume
- 249
- Issue
- 4970
- Pages
- 790-793
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1963872182
- Semantic Scholar
- be3dbcf0ed6239b54ab96520181db05f1ba0399f
- Cited by
- 539
- References
- 32
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 7 · 2023: 9 · 2022: 7 · 2021: 10 · 2020: 9 · 2019: 16 · 2018: 10 · 2017: 17 · 2016: 13 · 2015: 15 · 2014: 16 · 2013: 18 · 2012: 7
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hl033714-17, 5r37hl036461-09)
- National Heart, Lung, and Blood Institute (HL 33714, HL-36461, HL-33435)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- hypertriglyceridemia, apolipoprotein C-III, transgenic mice, gene overexpression, primary hypertriglyceridemia, secondary hypertriglyceridemia, triglyceride metabolism, gene dosage
- MeSH terms
- Animals, Apolipoproteins C, Chylomicrons, Cloning, Molecular, DNA Restriction Enzymes, DNA, Recombinant, Humans, Lipoproteins, VLDL, Mice, Inbred CBA, Mice, Inbred C57BL, Mice, Transgenic, Nucleic Acid Hybridization, RNA, Messenger, Triglycerides, Hypertriglyceridemia, Gene Expression, Mice, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.